title: Randomized phase II study of the neurokinin 1 receptor antagonist CJ-11,974 in the control of cisplatin-induced emesis.
abstract: OBJECTIVE
  To determine the efficacy and safety of the neurokinin type 1 receptor antagonist CJ-11,974 for the control of high-dose cisplatin-induced emesis.
  
  
  METHODS
  A double-blind, randomized, phase II design with a group sequential stopping rule was used in this study. Sixty-one patients with cancer who were receiving cisplatin at a dose of at least 100 mg/m2 for the first time were enrolled. All patients received granisetron 10 microg/kg and dexamethasone 20 mg intravenously 30 minutes before they were given cisplatin. Patients were randomly assigned to two groups: group 1 received CJ-11,974 100 mg, and group 2 received placebo orally 30 minutes before and 12 hours after cisplatin and then twice daily on days 2 through 5 after cisplatin. The primary end point was the percentage of patients who developed delayed emesis (emesis on the second to fifth days after cisplatin).
  
  
  RESULTS
  Thirty patients were enrolled in group 1, and 31 patients were enrolled in group 2. Fifty-eight patients were assessable for efficacy. Complete control of emesis (expressed as the percentage of patients who had no emesis) was as follows: day 1, 85.7% (group 1) and 66.7% (group 2) (P = .090); days 2 through 5, 67.8% (group 1) and 36.6% (group 2) (P = .0425, adjusted); days 1 through 5, 64.3% (group 1) and 30% (group 2) (P = .009). Patients in group 1 experienced significantly less nausea than patients in group 2 on day 1 (P = .024). Treatment was well tolerated in both groups.
  
  
  CONCLUSIONS
  We conclude from this exploratory phase II trial that CJ-11,974 is superior to placebo in controlling cisplatin-induced delayed emesis and may provide additive benefit in acute emesis and nausea control when combined with a 5-hydroxytryptamine-3 receptor antagonist and dexamethasone. Additional larger trials are indicated to confirm the clinical value of CJ-11,974.
authors.affiliation: Section of Medical Oncology, St. Elizabeth's Medical Center, Boston, MA 02135, USA. phesketh@aol.com
authors.forename: P J
authors.initials: PJ
authors.lastname: Hesketh
authors.forename: R J
authors.initials: RJ
authors.lastname: Gralla
authors.forename: R T
authors.initials: RT
authors.lastname: Webb
authors.forename: W
authors.initials: W
authors.lastname: Ueno
authors.forename: S
authors.initials: S
authors.lastname: DelPrete
authors.forename: M E
authors.initials: ME
authors.lastname: Bachinsky
authors.forename: N L
authors.initials: NL
authors.lastname: Dirlam
authors.forename: C B
authors.initials: CB
authors.lastname: Stack
authors.forename: S L
authors.initials: SL
authors.lastname: Silberman
mesh_terms: D000328:Adult; D000368:Aged; D000932:Antiemetics / Q000009:adverse effects / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D001555:Benzene Derivatives / Q000009:adverse effects / Q000627:therapeutic use*; D002945:Cisplatin / Q000009:adverse effects*; D003907:Dexamethasone / Q000627:therapeutic use; D004311:Double-Blind Method; D005260:Female; D017829:Granisetron / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D064729:Neurokinin-1 Receptor Antagonists; D014839:Vomiting / Q000139:chemically induced / Q000188:drug therapy / Q000517:prevention & control*
chemical_list: D000932:Antiemetics; D000970:Antineoplastic Agents; D001555:Benzene Derivatives; D002945:Cisplatin; D003907:Dexamethasone; D017829:Granisetron; D064729:Neurokinin-1 Receptor Antagonists; C120871:CJ 11974